BAMF Health

Running trials

• Recruiting

  Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)

  NCT07219238· Phase 2/3· Source

• Recruiting

  Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])

  NCT07831824· Phase 2/3· Source

• Not yet recruiting

  Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer

  NCT07781852· Early phase 1· Source

• Recruiting

  A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

  NCT07581184· Phase 1· Source

• Recruiting

  177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

  NCT07189871· Phase 1/2· Source

• Active, not recruiting

  Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

  NCT07214961· Phase 1· Source

• Recruiting

  A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

  NCT07020117· Phase 1· Source

• Recruiting

  Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

  NCT06562192· Phase 1· Source

• Active, not recruiting

  FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  NCT06402331· Phase 2· Source

• Active, not recruiting

  PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer

  NCT06074510· Phase 4· Source

• Recruiting

  Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

  NCT06056830· Phase 3· Source

• Recruiting

  Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

  NCT05636618· Phase 1/2· Source

• Recruiting

  64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

  NCT04868604· Phase 1/2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Prostate cancer6 recruiting
• Colorectal cancer5 recruiting
• Lung cancer4 recruiting
• Gastric and esophageal cancer3 recruiting
• Ovarian cancer3 recruiting
• Pancreatic cancer3 recruiting
• Triple-negative breast cancer3 recruiting
• Bladder cancer2 recruiting
• Head and neck cancer2 recruiting
• Cervical cancer1 recruiting
• Endometrial cancer1 recruiting
• Glioblastoma1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Neuroendocrine tumours1 recruiting
• Sarcoma1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Recruiting

  An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

  NCT05939414· Phase 3· Source

• Completed

  Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer

  NCT06129422· Phase 1· Source

• Completed

  Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers

  NCT05641896· Phase 2· Source